Biofrontera (NASDAQ:BFRI – Get Free Report) and NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a breakdown of current recommendations for Biofrontera and NRx Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biofrontera | 1 | 1 | 1 | 0 | 2.00 |
| NRx Pharmaceuticals | 2 | 0 | 6 | 0 | 2.50 |
NRx Pharmaceuticals has a consensus target price of $34.50, indicating a potential upside of 1,319.17%. Given NRx Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Biofrontera.
Volatility and Risk
Biofrontera has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500.
Insider and Institutional Ownership
10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Comparatively, 4.9% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Biofrontera and NRx Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biofrontera | $41.71 million | 0.33 | -$10.54 million | ($0.45) | -2.04 |
| NRx Pharmaceuticals | $1.23 million | 86.27 | -$28.62 million | ($0.55) | -4.42 |
Biofrontera has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Biofrontera and NRx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biofrontera | -13.78% | -145.81% | -31.30% |
| NRx Pharmaceuticals | -691.81% | N/A | -63.92% |
Summary
Biofrontera beats NRx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Biofrontera
Biofrontera Inc. (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing prescription dermatology products, with an emphasis on treatments for precancerous and cancerous skin conditions. The company primarily serves the U.S. dermatology market through a commercial organization that supports physicians and other healthcare providers. Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription medication used with photodynamic therapy to treat actinic keratoses.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company’s research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset. NRx’s lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
